COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01904643
Recruitment Status : Terminated (Accrual factor)
First Posted : July 22, 2013
Last Update Posted : October 29, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
David Iberri, Stanford University

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 13, 2015
Actual Study Completion Date : July 18, 2015